A state-of-the-art biotechnology facility acquired in Merck KGAA’s $13 million buyout of Serono SA in 2006 will be shuttered and listed for sale as part of the German pharma’s ongoing transformation effort.
In an April 24 announcement, Merck KGAA, the parent company, outlined significant changes at its pharmaceutical and drug-development division
Welcome to Pink Sheet
Create an account to read this article
Already a subscriber?